New drug shows promise in shrinking fatty liver
NCT ID NCT07481734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a daily injection of tesamorelin can safely reduce liver fat in adults with metabolic fatty liver disease (MASLD). About 120 participants will receive either the drug or a placebo for 52 weeks, along with lifestyle advice. The main goal is to measure changes in liver fat using MRI scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC STEATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a weekly shot help more people donate part of their liver?
- Could a probiotic supplement help reverse fatty liver?
- Could a probiotic supplement help reverse fatty liver?
- New drug HPG1860 shows promise in reducing liver fat in NASH patients
- New blood test may detect fatty liver before It's too late
- Gut health fix for HIV fatty liver? early trial tests probiotics